MedTrace Logo

Antimicrobial Drug Use and Resistant Staphylococcus Aureus

NCT01075451 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 41

Last updated 2013-05-20

No results posted yet for this study

Summary

The purpose of this investigation is to study the relationships between antimicrobial stewardship program efforts, antimicrobial drug use, and infection control efforts to the incidence rates of hospital acquired infections with Staphylococcus aureus in a sample of US academic medical center hospitals.

Conditions

  • Staphylococcus Aureus

Sponsors & Collaborators

  • University HealthSystem Consortium

    collaborator OTHER

  • Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

    collaborator INDUSTRY

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Ron E Polk, Pharm.D. · Virginia Commonwealth University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01075451 on ClinicalTrials.gov